title: Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
abstract: Valproic acid (VPA) has a narrow therapeutic range (50-100mg/l) and exhibits nonlinear protein binding. Additionally, VPA pharmacokinetics are dependent on age, induction status, and formulation; so titration and dosing vary between individuals. The aim of these simulations was to determine optimal intravenous (i.v.) loading dose, and i.v. and oral VPA maintenance regimens. A 5-min 15mg/kg loading dose resulted in total and free plasma VPA concentrations of approximately 65 and 7.5mg/l in children, and approximately 80 and 11mg/l in adults, 1h after the infusion; induction status had little effect. For uninduced children and adults, 7.5 and 3.5mg/kg q6h i.v. valproate sodium, initiated 6h after loading dose maintains therapeutic plasma VPA concentrations. The rapid decline of plasma VPA concentrations following an i.v. loading dose in combination with the delayed initial absorption of drug from delayed-release divalproex sodium tablets warrant beginning q12h oral maintenance regimens of delayed-release divalproex sodium within 2h of a loading dose in the uninduced population. Plasma VPA concentrations can be sustained in the therapeutic range using once-daily maintenance regimens of extended-release divalproex sodium tablets if initiated concurrently with i.v. loading dose in the uninduced population. A two-fold higher i.v. and oral maintenance regimen dose may be required in induced patients.
authors.affiliation: Abbott Laboratories, Department R4PK, Bldg. AP13A-3, 100 Abbott Park Road, 60064-6104, Abbott Park, IL, USA. sandeep.dutta@abbott.com
authors.forename: Sandeep
authors.initials: S
authors.lastname: Dutta
authors.forename: James C
authors.initials: JC
authors.lastname: Cloyd
authors.forename: G Richard
authors.initials: GR
authors.lastname: Granneman
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Collins
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000375:Aging / Q000378:metabolism; D000465:Algorithms; D000927:Anticonvulsants / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D002648:Child; D003198:Computer Simulation; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D017711:Nonlinear Dynamics; D011485:Protein Binding; D014635:Valproic Acid / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D003692:Delayed-Action Preparations; D014635:Valproic Acid